Eledon Pharmaceuticals
Logotype for Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals (ELDN) investor relations material

Eledon Pharmaceuticals Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Eledon Pharmaceuticals Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Tegoprubart, an anti-CD40L antibody, remains the focus of development in kidney and islet transplantation; no products are approved and no product sales revenue has been generated.

  • Q3 net loss narrowed to $3.9M from $17.5M, mainly due to a $17.0M non-cash warrant-liability fair-value gain; operating expenses increased to $21.7M.

  • Kidney-transplant extension data showed higher eGFR with tegoprubart than tacrolimus through month 24; planned registrational trials remain dependent on additional financing.

Financial highlights

  • Q3 R&D expense was $17.8M vs. $15.0M a year earlier; G&A was $3.9M vs. $4.1M, and operating expenses totaled $21.7M vs. $19.1M.

  • Q3 net loss was $3.9M, or $0.03 per share, vs. $17.5M, or $0.21 per share; excluding warrant fair-value changes, Q3 net loss was $21.0M vs. $18.0M.

  • 9M operating expenses were $65.7M vs. $61.8M, and net loss was $74.6M vs. $35.2M; warrant remeasurement shifted from a $22.9M gain to an $11.6M loss.

  • 9M operating cash use was $64.3M vs. $48.3M; quarter-end cash and equivalents were $6.9M, while cash, equivalents and short-term investments totaled $69.7M.

Outlook and guidance

  • Global Phase 3 LEGACY in kidney transplantation is planned for Q4 2026, subject to financing; expected enrollment is ~600, with a week-52 non-inferiority endpoint based on BPAR, graft loss and death.

  • FDA cleared the IND for a planned company-sponsored registrational-path islet-transplant study; initiation requires additional financing.

  • Other planned programs include an investigator-led de novo liver-transplant study; FDA guidance on the kidney xenotransplantation path to market is anticipated over the next 12 months.

  • Manufacturing and personnel costs are expected to rise as kidney Phase 3 and islet programs advance; current resources are not expected to fund planned operations for at least 12 months from financial-statement issuance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Eledon Pharmaceuticals earnings date

Logotype for Eledon Pharmaceuticals Inc
Q4 202625 Mar, 2027
Eledon Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Eledon Pharmaceuticals earnings date

Logotype for Eledon Pharmaceuticals Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Eledon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat autoimmune diseases, organ transplantation, and neurodegenerative disorders. The company’s lead program involves developing treatments that target CD40L, a key immune system pathway involved in immune response regulation. By modulating this pathway, Eledon aims to develop therapies that prevent organ transplant rejection and treat autoimmune conditions without the need for long-term immunosuppression. The company's innovative approach seeks to address significant unmet medical needs in these therapeutic areas. The company is headquartered in Irvine, California, and its shares are listed on the NASDAQ.